Search Results - "PORAYKO, M. K"

Hemosiderosis in cirrhosis: A study of 447 native livers by Ludwig, J, Hashimoto, E, Porayko, MK, Moyer, TP, Baldus, WP

“…BACKGROUND & AIMS: Hemosiderosis may have a detrimental effect on some chronic liver diseases. The aim of this study was to determine the prevalence and…”
Get full text

Long‐term results of patients undergoing liver transplantation for primary sclerosing cholangitis by Graziadei, Ivo W., Wiesner, Russell H., Marotta, Paul J., Porayko, Michael K., Hay, J. Eileen, Charlton, Michael R., Poterucha, John J., Rosen, Charles B., Gores, Gregory J., LaRusso, Nicholas F., Krom, Ruud A. F.

“…Liver transplantation is the only effective therapeutic option for patients with end‐stage liver disease due to primary sclerosing cholangitis (PSC). In this…”
Get full text

Use of fatty donor liver is associated with diminished early patient and graft survival by MARSMAN, W. A, WIESNER, R. H, RODRIGUEZ, L, BATTS, K. P, PORAYKO, M. K, HAY, J. E, GORES, G. J, KROM, R. A. F

“…It is well known that implantation of donor livers with severe fatty infiltration (>60%) is frequently associated with early hepatic dysfunction and an…”
Get full text

Iron overload in cirrhosis—HFE genotypes and outcome after liver transplantation by Brandhagen, David J., Alvarez, William, Therneau, Terry M., Kruckeberg, Kent E., Thibodeau, Stephen N., Ludwig, Jurgen, Porayko, Michael K.

“…Previously, we found appreciable hepatic iron deposition in one third of our patients undergoing liver transplantation (LTx) with approximately 10% of cases…”
Get full text

Recurrence of nonalcoholic steatohepatitis following liver transplantation by KIM, W. R, POTERUCHA, J. J, PORAYKO, M. K, DICKSON, E. R, STEERS, J. L, WIESNER, R. H

“…Patients with nonalcoholic steatohepatitis (NASH) may develop progressive liver dysfunction necessitating liver transplantation (OLT). We report the incidence…”
Get full text

Lactobacillemia in Liver Transplant Patients by Patel, R., Cockerill, F. R., Porayko, M. K., Osmon, D. R., Ilstrup, D. M., Keating, M. R.

“…Lactobacillemia is rare and, to our knowledge, previously undescribed in liver transplant patients. We reviewed the clinical records of all patients who had…”
Get full text

The economic impact of cytomegalovirus infection after liver transplantation by KIM, W. R, BADLEY, A. D, WIESNER, R. H, PORAYKO, M. K, SEABERG, E. C, KEATING, M. R, EVANS, R. W, DICKSON, E. R, KROM, R. A. F, PAYA, C. V

“…We studied the economic impact of cytomegalovirus (CMV) disease and its effective reduction with antiviral prophylaxis in liver transplant recipients. Analysis…”
Get full text

Optimal timing of liver transplantation for primary biliary cirrhosis by Kim, W. Ray, Wiesner, Russell H., Therneau, Terry M., Poterucha, John J., Porayko, Michael K., Evans, Roger W., Klintmalm, Goran B., Crippin, Jeffrey S., Krom, Ruud A., Dickson, E. Rolland

“…In 1989, we reported on the efficacy of liver transplantation in primary biliary cirrhosis (PBC) by demonstrating that the actual patient survival following…”
Get full text

Differences in NAFLD/NASH Management by Provider Specialty: Opportunities for Optimizing Multidisciplinary Care by Porayko, Michael K, Articolo, Amy, Cerenzia, Wendy, Coleman, Brandon, Patel, Daxa, Stacy, Sylvie

“…Purpose: Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are a part of a complex metabolic disease process requiring a…”
Get full text

Prophylaxis of cytomegalovirus infection in liver transplantation : A randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir by BADLEY, A. D, SEABERG, E. C, ZETTERMAN, R, STEERS, J. L, PAYA, C. V, PORAYKO, M. K, WIESNER, R. H, KEATING, M. R, WILHELM, M. P, WALKER, R. C, PATEL, R, MARSHALL, W. F, DEBERNARDI, M

“…The optimal prophylactic regimen to prevent cytomegalovirus (CMV) infection and disease in orthotopic liver-transplant patients remains to be established. We…”
Get full text

Bone disease in liver transplant recipients: incidence, timing, and risk factors by Porayko, M K, Wiesner, R H, Hay, J E, Krom, R A, Dickson, E R, Beaver, S, Schwerman, L

Get more information

Histological evidence for recurrence of primary biliary cirrhosis after liver transplantation by Balan, V, Batts, K P, Porayko, M K, Krom, R A, Ludwig, J, Wiesner, R H

“…Whether primary biliary cirrhosis recurs after orthotopic liver transplantation remains a controversial issue. Sixty consecutive patients with primary biliary…”
Get more information

Bone loss after orthotopic liver transplantation: FK 506 versus cyclosporine by Park, K M, Hay, J E, Lee, S G, Lee, Y J, Wiesner, R H, Porayko, M K, Krom, R A

Get more information

Hypertension after liver transplantation: A predictive role for pretreatment hemodynamics and effects of isradipine on the systemic and renal circulations by Taler, Sandra J, Textor, Stephen C, Canzanello, Vincent J, Schwartz, Lora, Porayko, Michael K, Wiesner, Russell H, Krom, Ruud A.F

“…Hypertension developing after liver transplantation during immunosuppression with cyclosporine A reflects an unusual hemodynamic transition from peripheral…”
Get full text

Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation by Porayko, M K, Textor, S C, Krom, R A, Hay, J E, Gores, G J, Richards, T M, Crotty, P H, Beaver, S J, Steers, J L, Wiesner, R H

“…We conducted a treatment trial to determine the relative toxicity of FK-506 and cyclosporine A (CSA) in liver transplant recipients. Between October 1990 and…”
Get more information

Role of endoscopic retrograde cholangiopancreatography after orthotopic liver transplantation by Wolfsen, H C, Porayko, M K, Hughes, R H, Gostout, C J, Krom, R A, Wiesner, R H

“…We reviewed the records of 20 liver transplant patients who underwent 28 procedures [endoscopic retrograde cholangiopancreatography (ERCP)] to rule out biliary…”
Get more information

Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection by Sandborn, W J, Hay, J E, Porayko, M K, Gores, G J, Steers, J L, Krom, R A, Wiesner, R H

“…Twelve consecutive liver transplant recipients with stable allograft function and cyclosporine nephrotoxicity were subjected to cyclosporine withdrawal in an…”
Get more information

Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension by Findlay, James Y., Plevak, David J., Krowka, Michael J., Sack, Elizabeth M., Porayko, Michael K.

“…Patients with end‐stage liver failure, portal hypertension, and associated pulmonary artery hypertension (portopulmonary hypertension [PPHTN]) have a high…”
Get full text

Liver transplantation: late complications of the biliary tract and their management by Porayko, M K, Kondo, M, Steers, J L

“…Even though the incidence of biliary complications has decreased over the years, the biliary tract is still a source of significant morbidity and graft failure…”
Get more information

Neoral compared to sandimmune is associated with a decrease in histologic severity of rejection in patients undergoing primary liver transplantation by GRAZIADEI, I. W, WIESNER, R. H, MAROTTA, P. J, PORAYKO, M. K, DAHLKE, L. J, WILSON, S. M, STEERS, J. L, KROM, R. A. F

“…In a randomized, controlled study we investigated the clinical efficacy of the microemulsion formulation of cyclosporine (Neoral) in comparison with Sandimmune…”
Get full text